Nonopioidergic mechanism mediating morphine-induced antianalgesia in the mouse spinal cord

J Pharmacol Exp Ther. 2004 Jul;310(1):240-6. doi: 10.1124/jpet.104.065334. Epub 2004 Mar 3.

Abstract

Intrathecal (i.t.) pretreatment with a low dose (0.3 nmol) of morphine causes an attenuation of i.t. morphine-produced analgesia; the phenomenon has been defined as morphine-induced antianalgesia. The opioid-produced analgesia was measured with the tail-flick (TF) test in male CD-1 mice. Intrathecal pretreatment with low dose (0.3 nmol) of morphine time dependently attenuated i.t. morphine-produced (3.0 nmol) TF inhibition and reached a maximal effect at 45 min. Intrathecal pretreatment with morphine (0.009-0.3 nmol) for 45 min also dose dependently attenuated morphine-produced TF inhibition. The i.t. morphine-induced antianalgesia was dose dependently blocked by the nonselective mu-opioid receptor antagonist (-)-naloxone and by its nonopioid enantiomer (+)-naloxone, but not by endomorphin-2-sensitive mu-opioid receptor antagonist 3-methoxynaltrexone. Blockade of delta-opioid receptors, kappa-opioid receptors, and N-methyl-D-aspartate (NMDA) receptors by i.t. pretreatment with naltrindole, nor-binaltorphimine, and (-)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801), respectively, did not affect the i.t. morphine-induced antianalgesia. Intrathecal pretreatment with antiserum against dynorphin A(1-17), [Leu]-enkephalin, [Met]-enkephalin, beta-endorphin, cholecystokinin, or substance P also did not affect the i.t. morphine-induced antianalgesia. The i.t. morphine pretreatment also attenuated the TF inhibition produced by opioid muagonist [D-Ala2, N-Me-Phe4,Gly-ol5]-enkephalin, delta-agonist deltorphin II, and kappa-agonist U50,488H. It is concluded that low doses (0.009-0.3 nmol) of morphine given i.t. activate an antianalgesic system to attenuate opioid mu-, delta-, and kappa-agonist-produced analgesia. The morphine-induced antianalgesia is not mediated by the stimulation of opioid mu-, delta-, or kappa-receptors or NMDA receptors. Neuropeptides such as dynorphin A(1-17), [Leu]-enkephalin, [Met]-enkephalin, beta-endorphin, cholecystokinin, and substance P are not involved in this low-dose morphine-induced antianalgesia.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Analgesia*
  • Animals
  • Dizocilpine Maleate / pharmacology
  • Drug Interactions
  • Drug Tolerance
  • Dynorphins / immunology
  • Dynorphins / metabolism
  • Enkephalins / immunology
  • Enkephalins / metabolism
  • Male
  • Mice
  • Morphine / administration & dosage*
  • Morphine / therapeutic use
  • Naloxone / pharmacology
  • Naltrexone / analogs & derivatives*
  • Naltrexone / pharmacology
  • Oligopeptides / metabolism
  • Pain / drug therapy*
  • Pain Measurement / drug effects
  • Receptors, Opioid, delta / agonists
  • Receptors, Opioid, kappa / agonists
  • Receptors, Opioid, mu / agonists
  • Spinal Cord / drug effects*
  • Substance P / immunology
  • Substance P / metabolism
  • beta-Endorphin / immunology
  • beta-Endorphin / metabolism

Substances

  • 3-methoxynaltrexone
  • Enkephalins
  • Oligopeptides
  • Receptors, Opioid, delta
  • Receptors, Opioid, kappa
  • Receptors, Opioid, mu
  • Substance P
  • Naloxone
  • norbinaltorphimine
  • endomorphin 2
  • Naltrexone
  • beta-Endorphin
  • Dizocilpine Maleate
  • Dynorphins
  • Morphine
  • naltrindole